PubMed

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.

Aronow HD.

Curr Control Trials Cardiovasc Med. 2002 Jan 7;3(1):3.PMID: 11985777 [PubMed - as supplied by publisher]Related articlesFree article

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

Waters D, Schwartz GG, Olsson AG.

Curr Control Trials Cardiovasc Med. 2001;2(3):111-114.PMID: 11806782 [PubMed - as supplied by publisher]Related articlesFree article

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.

Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators.

Circulation. 2002 Sep 24;106(13):1690-5.PMID: 12270864 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.PMID: 15262833 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.PMID: 17910519 [PubMed - indexed for MEDLINE]Related articles

Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

Schwartz GG, Olsson AG, Szarek M, Sasiela WJ.

Diabetes Care. 2005 Oct;28(10):2508-13.PMID: 16186288 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.

Gresser U, Gathof BS.

Eur J Med Res. 2004 Jan 26;9(1):1-17. Review.PMID: 14766335 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin: its clinical role in cerebrovascular prevention.

Gaspardone A, Arca M.

Drugs. 2007;67 Suppl 1:55-62. Review.PMID: 17910521 [PubMed - indexed for MEDLINE]Related articles

Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).

Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ.

Am J Cardiol. 2007 Mar 1;99(5):632-5. Epub 2007 Jan 9.PMID: 17317362 [PubMed - indexed for MEDLINE]Related articles

Early initiation of treatment with statins in acute coronary syndromes.

Olsson AG, Schwartz GG.

Ann Med. 2002;34(1):37-41. Review.PMID: 12014432 [PubMed - indexed for MEDLINE]Related articles

Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation.

Waters DD, Ku I.

J Am Coll Cardiol. 2009 Oct 6;54(15):1434-7.PMID: 19796736 [PubMed - indexed for MEDLINE]Related articles

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.

Circulation. 2003 Sep 30;108(13):1560-6. Epub 2003 Sep 15.PMID: 12975259 [PubMed - indexed for MEDLINE]Related articlesFree article

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators.

J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96.PMID: 19497447 [PubMed - indexed for MEDLINE]Related articles

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.

Ray KK, Cannon CP.

Curr Opin Lipidol. 2004 Dec;15(6):637-43. Review.PMID: 15529022 [PubMed - indexed for MEDLINE]Related articles

A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.

Buller N, Gillen D, Casciano R, Doyle J, Wilson K.

Pharmacoeconomics. 2003;21 Suppl 1:25-32.PMID: 12648032 [PubMed - indexed for MEDLINE]Related articles

Are early clinical effects of cholesterol lowering mediated through effects on inflammation?

Olsson AG, Schwartz GG, Jonasson L, Linderfalk C.

Acta Physiol Scand. 2002 Oct;176(2):147-50.PMID: 12354174 [PubMed - indexed for MEDLINE]Related articles

Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.

Austin PC, Mamdani MM.

Circulation. 2005 Aug 30;112(9):1296-300. Epub 2005 Aug 22.PMID: 16116054 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.

Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2008 Sep 9;52(11):914-20.PMID: 18772061 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca M.

Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles